Developmental strategy for swellable/erodible matrix tablet of mirabegron: quality by design approach with various geometric properties and pharmacokinetic evaluation

다국어 초록 (Multilingual Abstract)

Purpose This study aimed to establish a developmental strategy for swellable and erodible matrix tablets containing mirabegron using a quality by design approach with geometric properties such as gel strength, erosion rate, and swelling rate.
Methods The design of the experiment (DoE) was used to investigate the effects of critical material attributes (CMAs) on critical quality attributes (CQAs) and geometric properties. Pearson correlation coefficients were used to determine the relationship between geometric properties and CQAs. To evaluate the pharmacokinetics of mirabegron following oral administrations of the test and reference formulations, in vivo pharmacokinetic study was carried out using Beagle dogs.
Results As a result of DoE, (%) dissolved drug amount and geometric properties were significantly related to CMAs. A robust design space was established with low absolute and relative biases between prediction and experimental results. Pearson correlation coefficients showed significant correlations between (%) dissolved drug amount and geometric properties. The geometric mean ratios of the maximum plasma concentration and area under the concentration–time curve between test and reference formulations were 0.954 and 1.050, respectively. No significant differences in all pharmacokinetic parameters were observed between reference and test drug-treated groups (p < 0.05, t-test).
Conclusion These results show the usefulness of the developmental strategies using various geometric properties while developing a swellable/erodible matrix tablet.

참고문헌 (Reference)

1 Bettini R, "Translocation of drug particles in HPMC matrix gel layer : effect of drug solubility and influence on release rate" 70 : 383-391, 2001

2 Nokhodchi A, "The role of oral controlled release matrix tablets in drug delivery systems" 2 : 175-187, 2012

3 Jain AK, "The influence of hydroxypropyl methylcellulose(HPMC)molecular weight, concentration and effect of food on in vivo erosion behavior of HPMC matrix tablets" 187 : 50-58, 2014

4 Viridén A, "The effect of chemical heterogeneity of HPMC on polymer release from matrix tablets" 36 : 392-400, 2009

5 Suzuki T, "The change in characteristics of microcrystalline cellulose during wet granulation using a high-shear mixer" 53 : 609-616, 2001

6 Kavanagh N, "Swelling and erosion properties of hydroxypropylmethylcellulose(hypromellose)matrices—influence of agitation rate and dissolution medium composition" 279 : 141-152, 2004

7 Wadher KJ, "Study on sustained-release metformin hydrochloride from matrix tablet : influence of hydrophilic polymers and in vitro evaluation" 1 : 157-163, 2011

8 Sujja-Areevath J, "Relationship between swelling, erosion and drug release in hydrophilic natural gum mini-matrix formulations" 6 : 207-217, 1998

9 Bonthagarala B, "Quality-by-Design based development and characterization of pioglitazone loaded liquisolid compact tablets with improved biopharmaceutical attributes" 51 : 345-355, 2019

10 Skoug JW, "Qualitative evaluation of the mechanism of release of matrix sustained release dosage forms by measurement of polymer release" 27 : 227-245, 1993

11 Wang Z, "Process analysis and optimization of continuous pharmaceutical manufacturing using flow sheet models" 107 : 77-91, 2017

12 Medarevic D, "Polyethylene oxides as matrix forming agents: direct compression vs. wet granulation" 2012

13 Apicella A, "Poly(ethylene oxide)(PEO)and different molecular weight PEO blends monolithic devices for drug release" 14 : 83-90, 1993

14 De Haan P, "Oral controlled release dosage forms. A review" 6 : 57-67, 1984

15 Colombo P, "Observation of swelling process and diffusion front position during swelling in hydroxypropyl methyl cellulose(HPMC)matrices containing a soluble drug" 61 : 83-91, 1999

16 Abrams P, "Muscarinic receptor antagonists for overactive bladder" 100 : 987-1006, 2007

17 Kawashima Y, "Low-substituted hydroxypropylcellulose as a sustained-drug release matrix base or disintegrant depending on its particle size and loading in formulation" 10 : 351-355, 1993

18 Sako K, "Influence of water soluble fillers in hydroxypropylmethylcellulose matrices on in vitro and in vivo drug release" 81 : 165-172, 2002

19 Johnson JL, "Influence of ionic strength on matrix integrity and drug release from hydroxypropyl cellulose compacts" 90 : 151-159, 1993

20 Huanbutta K, "Impact of salt form and molecular weight of chitosan on swelling and drug release from chitosan matrix tablets" 97 : 26-33, 2013

21 Parikh DM, "Handbook of pharmaceutical granulation technology" CRC Press 2005

22 Goldoozian S, "Gel strength of hydrophilic matrix tablets in terms of in vitro robustness" 38 : 1297-1306, 2021

23 Kumar VS, "Formulation and in vitro evaluation of mirabegron extended release tablets" 14 : 69-77, 2023

24 Rudnic EM, "Evaluations of the mechanism of disintegrant action" 8 : 87-109, 1982

25 Buser N, "Efficacy and adverse events of antimuscarinics for treating overactive bladder : network meta-analyses" 62 : 1040-1060, 2012

26 Badawy SIF, "Effect of process parameters on compressibility of granulation manufactured in a high-shear mixer" 198 : 51-61, 2000

27 Benali M, "Effect of operating conditions and physico-chemical properties on the wet granulation kinetics in high shear mixer" 190 : 160-169, 2009

28 Colombo P, "Drug diffusion front movement is important in drug release control from swellable matrix tablets" 84 : 991-997, 1995

29 Brady J, "Developing solid oral dosage forms" Elsevier 181-223, 2017

30 Wang L, "Design and evaluation of hydrophilic matrix system containing polyethylene oxides for the zero-order controlled delivery of water-insoluble drugs" 18 : 82-92, 2017

31 Mastropietro DJ, "Comprehensive biomaterials II" Elsevier 430-444, 2017

32 Hakimi Z, "Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada" 20 : 614-622, 2017

33 Davies WL, "Batch production of pharmaceutical granulations in a fluidized bed I : effects of process variables on physical properties of final granulation" 60 : 1869-1874, 1971

34 Mehta RY, "Application of ethylcellulose coating to hydrophilic matrices : a strategy to modulate drug release profile and reduce drug release variability" 15 : 1049-1059, 2014

35 Jamzad S, "Analysis of macromolecular changes and drug release from hydrophilic matrix systems" 292 : 75-85, 2005

36 Shojaee S, "An investigation on the effect of polyethylene oxide concentration and particle size in modulating theophylline release from tablet matrices" 16 : 1281-1289, 2015

37 Hansuld EM, "A review of monitoring methods for pharmaceutical wet granulation" 472 : 192-201, 2014

38 Shirai Y, "A novel fine granule system for masking bitter taste" 16 : 172-177, 1993

39 Borgquist P, "A model for the drug release from a polymer matrix tablet—effects of swelling and dissolution" 113 : 216-225, 2006